The VLA-4–Mediated Adhesion and Expression of the Leukemic (CD10+) Cell Populations in B-ALL Patients
| Patient No. . | CD10* . | VLA-4 Adhesion† . | VLA-4* . | ||
|---|---|---|---|---|---|
| Medium . | PMA . | TS2/16 . | |||
| d1 | + | +++ | +++ | +++ | +++ |
| d2 | ++ | +++ | +++ | +++ | +++ |
| d3 | ++ | +++ | +++ | +++ | +++ |
| d4 | ++ | +++ | +++ | +++ | +++ |
| 7 | +++ | +++ | +++ | +++ | +++ |
| 1‡ | +++ | +++ | +++ | +++ | +++ |
| 9 | ++ | +++ | +++ | +++ | +++ |
| 4 | ++ | +++ | +++ | +++ | +++ |
| 62-153 | + | +++ | +++ | +++ | +++ |
| 14 | +++ | +++ | +++ | +++ | ++ |
| 5 | +++ | +++ | +++ | +++ | ++ |
| 15 | ++ | ++ | +++ | +++ | +++ |
| 12 | +++ | ++ | +++ | +++ | ++ |
| 8‡ | +++ | ++ | +++ | +++ | ++ |
| 20 | ++ | ++ | +++ | +++ | ++ |
| 17 | ++ | ++ | ++ | +++ | +++ |
| 82-155 | + | ++ | ++ | +++ | ++ |
| 16 | + | ++ | ++ | +++ | + |
| 12-155 | + | ++ | ++ | ++ | + |
| 2 | −2-154 | + | + | +++ | ++ |
| 11‡ | +++ | + | + | +++ | ++ |
| 10 | ++ | + | + | +++ | ++ |
| 3 | ++ | + | + | +++ | ++ |
| 13 | + | + | + | +++ | ++ |
| 112-155 | + | + | + | ++ | ++ |
| 19 | ++ | + | + | ++ | + |
| 18 | −2-154 | + | + | ++ | ++ |
| Patient No. . | CD10* . | VLA-4 Adhesion† . | VLA-4* . | ||
|---|---|---|---|---|---|
| Medium . | PMA . | TS2/16 . | |||
| d1 | + | +++ | +++ | +++ | +++ |
| d2 | ++ | +++ | +++ | +++ | +++ |
| d3 | ++ | +++ | +++ | +++ | +++ |
| d4 | ++ | +++ | +++ | +++ | +++ |
| 7 | +++ | +++ | +++ | +++ | +++ |
| 1‡ | +++ | +++ | +++ | +++ | +++ |
| 9 | ++ | +++ | +++ | +++ | +++ |
| 4 | ++ | +++ | +++ | +++ | +++ |
| 62-153 | + | +++ | +++ | +++ | +++ |
| 14 | +++ | +++ | +++ | +++ | ++ |
| 5 | +++ | +++ | +++ | +++ | ++ |
| 15 | ++ | ++ | +++ | +++ | +++ |
| 12 | +++ | ++ | +++ | +++ | ++ |
| 8‡ | +++ | ++ | +++ | +++ | ++ |
| 20 | ++ | ++ | +++ | +++ | ++ |
| 17 | ++ | ++ | ++ | +++ | +++ |
| 82-155 | + | ++ | ++ | +++ | ++ |
| 16 | + | ++ | ++ | +++ | + |
| 12-155 | + | ++ | ++ | ++ | + |
| 2 | −2-154 | + | + | +++ | ++ |
| 11‡ | +++ | + | + | +++ | ++ |
| 10 | ++ | + | + | +++ | ++ |
| 3 | ++ | + | + | +++ | ++ |
| 13 | + | + | + | +++ | ++ |
| 112-155 | + | + | + | ++ | ++ |
| 19 | ++ | + | + | ++ | + |
| 18 | −2-154 | + | + | ++ | ++ |
Expression (mean fluorescence): −, 0 to 10; +/−, 11 to 30; +, 31 to 90; ++, 91 to 150; and +++, >150 (VLA-4 expression was measured on the CD10+ cells using dual fluorescence analysis).
Adhesion (%): −, 0 to 5; +/−, 6 to 10; +, 11 to 20; ++, 21 to 50; and +++, 51 to 100.
CD10bright.
CD34+.
CD10dim.
Gated by forward/side scatter. The percentage of leukemic cells was based on morphological data and immunophenotyping.